Genomtec enables partners to embed advanced, isothermal molecular diagnostics into their own products and workflows—spanning point‑of‑care instruments, near‑patient services, and centralized laboratory offerings. Our platform combines photonic, contactless heating and fluorescence detection with a passive microfluidic reaction card and semi‑quantitative analytics. The result is rapid, accurate, and economical testing with mid‑plex capability, low energy consumption, and a user experience optimized for near-patient environments.
We co‑develop companion and complementary diagnostic solutions that stratify patients for targeted therapies and accelerate clinical trial enrolment. Genomtec’s isothermal variant‑detection approach supports multi‑mutation panels, while maintaining high analytical specificity with low VAF and avoiding non‑specific amplification.
Clinical workflows can be executed near the patient, delivering actionable results typically within the same visit. Engagements include analytical and clinical validation, alignment to IVDR pathways for CDx devices, and full integration of ethics, regulatory, and quality processes so that partners can move from feasibility to registration with confidence.
For partners seeking an end‑to‑end solution, Genomtec provides turnkey assay development, reaction cards, and instrument integration—including OEM variants. The Genomtec platform uses photonic, contactless heating with multi‑zone temperature control to shorten amplification times and improve assay robustness. Paired with a passive microfluidic card, the system delivers mid‑plex testing without compromising accuracy. In typical infectious‑disease scenarios, the integrated analytical phase ranges from few minutes, while the workflow remains low‑power and intuitive for clinicians. We handle technology transfer, manufacturability, and regulatory documentation to streamline productization.
“Genomtec Inside” brings our core technology modules—optical heating and detection engine, passive microfluidic card, and analytical/interpretation software—into partner devices and systems. Implementations are tailored to OEM/ODM requirements and can be embedded into existing hardware and software architectures. We design and document integrations to meet ISO 13485 quality management, IEC 62304 medical software life‑cycle, and ISO 14971 risk‑management standards, enabling partners to expand their portfolios with near‑patient testing while preserving regulatory compliance and a consistent user experience.
Genomtec designs and develops RT‑LAMP assays from first principles. We select and optimize primers, formulate reaction mixes, stabilize reagents, and perform analytical and clinical validation. Compared with conventional PCR, LAMP operates at a constant temperature, tolerates common sample inhibitors, and employs multiple primer sites for high specificity and sensitivity, reducing time to result.
We provide ready‑to‑use laboratory kits and consumables, including rapid RT‑LAMP kits bearing CE‑IVD marking for selected pathogens. Lyophilized reagents simplify shipping and storage and reduce total cost of ownership. Kits are compatible with standard laboratory instrumentation and are designed for future migration to partners’ platforms, making roll‑out and scale‑up straightforward across laboratory networks and clinical sites.
Partners can license Genomtec’s intellectual property portfolio across defined fields of use—covering hardware modules, microfluidic reaction cards, assay chemistries, and primer‑design methodologies. Genomtec holds a growing set of granted patents and many pending applications spanning photonic heating, microfluidics, and proprietary reaction formulations across multiple jurisdictions. We offer non‑exclusive licenses or negotiate exclusivity for specified clinical indications, market segments, and territories, aligning technology access to partners’ strategic roadmaps.
Genomtec is developing an AI‑powered pipeline to design primers for isothermal amplification, applying reinforcement learning, generative flow networks, sequence models with reverse‑complement equivariance, and explainable‑AI techniques. The objective is to materially increase the proportion of candidate primer sets that succeed in vitro, shorten development cycles, and reduce prototyping costs—whether for infectious‑disease assays or CDx panels.
Genomtec is developing an AI‑powered pipeline to design primers for isothermal amplification, applying reinforcement learning, generative flow networks, sequence models with reverse‑complement equivariance, and explainable‑AI techniques. The objective is to materially increase the proportion of candidate primer sets that succeed in vitro, shorten development cycles, and reduce prototyping costs—whether for infectious‑disease assays or CDx panels. The program is being implemented with direct commercialization in mind: partners can access the capability as a design service or through licensing, accelerating time‑to‑market for new tests and menu expansions.
